Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2013, Article ID 809787, 8 pages
Research Article

Preemptive Treatment of Nausea and Vomiting of Pregnancy: Results of a Randomized Controlled Trial

The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, 555 University Avenue, Toronto, ON, Canada M5G 1X8

Received 13 November 2012; Revised 20 December 2012; Accepted 21 December 2012

Academic Editor: Enrique Hernandez

Copyright © 2013 Caroline Maltepe and Gideon Koren. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objectives. To determine whether the initiation of treatment (preemptive treatment) before the symptoms of nausea and vomiting of pregnancy (NVP) versus when the symptoms begin can improve the outcome in patients at a high risk for recurrence of severe NVP. Study Design. Prospective, randomized controlled trial. Results. Preemptive therapy conferred a significant reduction in HG as compared to the previous pregnancy ( . In the preemptive arm, there were 2.5-fold fewer cases of moderate-severe cases of NVP than those in the control group (15.4% versus 39.13%) in the first 3 weeks of NVP ( . In the preemptive group, significantly more women had their NVP resolved before giving birth (78.2% versus 50%) ( . Conclusions. Preemptive treatment with antiemetics is superior to the treatment that starts only when the symptoms have already occurred in decreasing the risk of severe forms of NVP.